Print

Genentech (RHHBY) Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States  
12/16/2010 9:29:57 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), confirmed that following the reviews of AvastinĀ® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities:
//-->